Antiva Biosciences
Clinical-stage biotechnology company developing non-surgical therapeutic candidates to treat pre-cancerous cervical lesions and other HPV-related diseases.
Website
https://www.antivabio.comLocation
San Francisco Bay Area, California, USA
Founded
2014
Investors
1
Categories
biotech, oncology, hpv, infectious-disease, therapeutics
Notes
Antiva Biosciences is a clinical-stage biotechnology company developing novel non-surgical therapeutic candidates to treat pre-cancerous cervical lesions caused by high-risk human papillomavirus (HPV). The company's approach aims to provide an alternative to surgical procedures like LEEP (loop electrosurgical excision procedure) for treating cervical dysplasia.
The lead candidate ATV-2000 is designed to eliminate HPV-infected cells while preserving normal cervical tissue, potentially offering a less invasive treatment option for women with cervical intraepithelial neoplasia (CIN).
Team
- Leadership team developing HPV therapeutics
Additional Research Findings
- Non-surgical approach to treating HPV-related pre-cancers
- Lead candidate ATV-2000 for cervical dysplasia
- Targeting cervical intraepithelial neoplasia (CIN) 2/3
- Alternative to surgical excision procedures
- Focus on preserving cervical tissue and fertility
- Addressing unmet need in HPV disease treatment
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Adjuvant Capital | Washington, DC, USA | biotech-focused | seedseries-a+3 | 16 |